MCCOY JOHN A. JR. 4

What Happened
John A. McCoy Jr., Vice President and Controller of Abbott Laboratories (ABT), received equity awards on February 24, 2026 totaling 27,524 shares: 5,373 shares and 22,151 derivative shares (performance-based restricted stock). The reported acquisition price for both items is $0.00 (these are grants/awards, not open-market purchases), so no cash was paid.

Key Details

• Transaction date: February 24, 2026; Form 4 filed February 26, 2026 (timely within the usual 2-business-day window).
• Reported acquisitions: 5,373 shares (award A) and 22,151 shares (derivative award A). Combined = 27,524 shares; reported price $0.00; total cash value at grant $0.
• Footnote F1: The 22,151 shares are a performance-based restricted stock award under Abbott’s 2017 Incentive Stock Program. The award has a 3-year term; no more than 1/3 vests in any year and vesting is contingent on Abbott meeting a minimum return-on-equity target. The award allows withholding of shares for tax purposes (tax withholding).
• Footnote F2: Filing notes a balance in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026.
• Footnote F3: The filing also references an employee stock option granted under the 2017 Incentive Stock Program that vests in annual increments (7,383 on 2/24/2027; 7,384 on 2/24/2028; 7,384 on 2/24/2029).
• Transaction type: A = Award/Grant; derivative designation indicates performance-based restricted stock rather than an open-market trade.

Context
These transactions are grants of compensation (not purchases or sales). Performance-based restricted stock awards vest only if specified performance targets are met, so they do not represent an immediate increase in tradable shares unless and until vesting conditions are satisfied (and tax-withholding mechanics may reduce delivered shares). For retail investors, awards like this are routine executive compensation and should not be interpreted alone as a directional signal about the insider’s view of the stock.